Oncology

Latest News

Photo courtesy of SpringWorks Therapeutics
FDA Approves First Treatment for Rare Noncancerous Tumors

November 28th 2023

Ogsiveo will be available within five to 10 business days to treat patients with desmoid tumors. It will launch with a price of $29,000 for a 30-day supply.

Janssen Submits Supplemental Application for Rybrevant in NSCLC
Janssen Submits Supplemental Application for Rybrevant in NSCLC

November 21st 2023

FDA to Hold Advisory Meeting for Abecma in Earlier Treatment of Multiple Myeloma
FDA to Hold Advisory Meeting for Abecma in Earlier Treatment of Multiple Myeloma

November 21st 2023

FDA Approves First-in-Class Therapy for HR Positive Breast Cancer
FDA Approves First-in-Class Therapy for HR Positive Breast Cancer

November 20th 2023

Bayer Recalls One Lot of Vitrakvi Because of Contamination
Bayer Recalls One Lot of Vitrakvi Because of Contamination

November 20th 2023

Latest CME Events & Activities

More News

Site Logo

FDA backs new biosimilar, plus 2 more approvals

Christine Blank
June 11th 2018

FDA approved the first biosimilar to Neulasta, as well as a new combination treatment for osteoarthritis pain and hypertension and a new drug to treat chronic lymphocytic leukemia.

Cancer drug prices rise despite Trump plan

Cancer drug prices rise despite Trump plan

Christine Blank
June 11th 2018

The manufacturer of two cancer drugs hiked the price on the medicines despite President Donald Trump’s new plan to lower drug prices.

Site Logo

New treatment for advanced kidney cancer approved

December 20th 2017

FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).

<1
...
678910
© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact